Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.

医学 易普利姆玛 转移性黑色素瘤 黑色素瘤 肿瘤科 内科学 重症监护医学 皮肤病科 癌症 免疫疗法 癌症研究
作者
Jarrett Failing,Heidi D. Finnes,Lisa A. Kottschade,Jacob B. Allred,Svetomir N. Markovic
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15_suppl): e21038-e21038 被引量:2
标识
DOI:10.1200/jco.2016.34.15_suppl.e21038
摘要

e21038 Background: Ipilimumab can induce long-term survival in up to 20% of patients with metastatic melanoma, however response comes with high rates of immune-related adverse events (irAEs). Concurrent chronic medications may impact the patient’s immune system, possess anti-melanoma properties, and potentially affect clinical outcomes (efficacy and/or toxicity). This retrospective study sought to describe the influence of 12 classes of concomitant chronic medications used by metastatic melanoma patients undergoing therapy with ipilimumab. Methods: Retrospective study of 159 adults who received ipilimumab for metastatic melanoma at Mayo Clinic in Rochester, MN from March 1, 2011 through December 31, 2014. Data on patient characteristics, best tumor response, irAEs, progression, death, and use of chronic medications (statins, metformin, beta blockers, ACE/ARBs, calcium channel blockers, aspirin, NSAIDs, H1 and H2 receptor antagonists, proton pump inhibitors, antidepressants, and vitamin D supplements) were abstracted from the electronic medical record. For the analysis of best tumor response and irAEs, a case-control analysis was employed. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan Meier method and Cox Proportional Hazard modeling. Results: Of the 12 concomitant medication classes, only proton pump inhibitors (PPIs) were found to have an increased odds of experiencing a partial response (PR) or complete response (CR) to ipilimumab (OR, 3.73; CI 1.26-11.04; p = .02). While not significant, PPI use trended towards improved OS and PFS (HR, 0.44; CI 0.17-1.15; p = .09; and HR, 0.6; CI 0.34-1.06; p = .08; respectively). Likewise, H2 antagonist use may result in an increased odds of PR or CR (OR, 5.27; CI 0.99-28.1; p = .05). No medication class was associated with increased risk of grade 3/4 irAEs. Conclusions: Patients on PPIs may be more likely to experience a PR/CR following ipilimumab therapy. Due to the small sample size and retrospective nature of this work, these finding are only descriptive and support further study. Other classes of chronic medications did not produce statistically significant effects for any of the measured outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
柳行天完成签到 ,获得积分10
刚刚
科目三应助阳光易真采纳,获得30
5秒前
yoyo发布了新的文献求助10
5秒前
思源应助Wl采纳,获得10
7秒前
共享精神应助橘笙采纳,获得10
8秒前
耍酷问兰发布了新的文献求助10
9秒前
科研通AI2S应助nczpf2010采纳,获得10
11秒前
搜集达人应助杜兰特工队采纳,获得10
16秒前
热心市民小红花应助牛马采纳,获得10
18秒前
热心市民小红花应助牛马采纳,获得10
18秒前
18秒前
Ava应助WJM采纳,获得10
22秒前
科研通AI2S应助nczpf2010采纳,获得10
23秒前
酷酷飞烟发布了新的文献求助10
23秒前
Bressanone发布了新的文献求助10
25秒前
李健的小迷弟应助老吴采纳,获得10
25秒前
大气的雅山完成签到,获得积分10
27秒前
shaoshao86完成签到,获得积分10
33秒前
33秒前
华仔应助科研通管家采纳,获得10
33秒前
逆时针应助科研通管家采纳,获得10
33秒前
MchemG应助科研通管家采纳,获得10
33秒前
研友_VZG7GZ应助科研通管家采纳,获得10
33秒前
wang应助科研通管家采纳,获得10
33秒前
wang应助科研通管家采纳,获得10
33秒前
ding应助科研通管家采纳,获得10
33秒前
上官若男应助科研通管家采纳,获得10
34秒前
思源应助科研通管家采纳,获得10
34秒前
田様应助科研通管家采纳,获得10
34秒前
小北发布了新的文献求助10
34秒前
NexusExplorer应助Quinna采纳,获得10
36秒前
37秒前
37秒前
量子星尘发布了新的文献求助10
39秒前
WJM发布了新的文献求助10
43秒前
老吴发布了新的文献求助10
44秒前
45秒前
佳语妍说完成签到,获得积分10
46秒前
47秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073